Our strategy
Innovative Biosimilars for Rare Diseases — Health, Sovereignty, and Sustainable Impact.
At NOVUSPHARM, our strategy is built upon a firm and unwavering belief: every Algerian patient deserves fair and equitable access to high-quality biological treatments — including for the rarest conditions.
Our dedication to biosimilars in rare diseases reflects a clear commitment: reducing therapeutic inequalities, fostering local medical excellence, and contributing to Algeria’s healthcare sovereignty.
Strengthening Healthcare Through Innovation and Commitment
Our progress is driven by a clear vision and decisive action. We are dedicated to building a stronger, more resilient pharmaceutical industry in Algeria.
Our commitment extends beyond delivering therapies; we aim to create lasting value for patients, healthcare professionals, and the national economy.
Bringing innovation where it is most needed
Focuses on selecting next-generation biosimilars meeting international standards to expand treatment options for rare diseases.
Investing in technology transfer
Highlights engagement in transferring know-how, enabling local manufacturing, and building industrial capabilities for national pharmaceutical independence.
Creating a positive impact on public health and the national economy
Discusses offering reliable, accessible, and cost-effective therapies to ease the financial burden on the healthcare system while ensuring optimal patient care.
Being a trusted partner to the Algerian healthcare system
Aspires to be a key player working with authorities, professionals, and researchers to build an ethical, forward-thinking, and resilient medical future.
Our vision
We stand for an Algerian pharmaceutical industry rooted in innovation and sovereignty. As a human-scale company with a national ambition, we aim to restore hope for patients and reduce the strain on our healthcare economy.
We are committed to playing a key role in Algeria's industrial renewal, driving progress that benefits all.
